Dosage and Administration
Dosing Regimen
The starting dose is 3 mg once daily, administered on an empty stomach (1 hour before or 2 hours after a meal). The dose may be adjusted based on the patient’s body weight, platelet count, and target platelet level.
Treatment Duration
The treatment course generally does not exceed 5 days to avoid excessive platelet elevation and thrombotic risk due to prolonged stimulation.
Important Precautions
Drug Interactions
Avoid co-administration with antacids (e.g., aluminum hydroxide); allow at least 2 hours between doses.
Use with caution when combined with strong CYP3A4 inhibitors or inducers.
Thrombosis Risk Monitoring
Elevated platelet counts may increase thrombotic risk. Platelet levels should be monitored regularly, especially in the later phase of treatment.
Adverse Reactions and Contraindications
Common Side Effects
Mild reactions: headache, nausea, fatigue, etc.
Laboratory abnormalities: elevated bilirubin, elevated liver enzymes (liver function monitoring required).
Serious Risks
Thrombotic events: rare but potentially life‑threatening, including portal vein thrombosis, deep vein thrombosis, etc.
Worsening liver function: close monitoring is required in patients with chronic liver disease.
Contraindicated Populations
Patients with hypersensitivity to any ingredient of lusutrombopag.
Patients with active thrombosis or a history of thrombosis.
Patients with severe hepatic impairment (Child‑Pugh Class C) require careful evaluation.
